RNA-Targeting Lends Renewed Focus to Gene Therapy Development Efforts

Video

Locanabio CEO James Burns, PhD, shares his outlook on the quickly changing landscape of gene therapy research.

No one can deny the lightning speed at which the gene and cell therapy space is advancing on a daily basis, but the ongoing evolution is particularly sweet for long-time industry players like James Burns, PhD, chief executive officer of Locanabio, Inc., a clinical-stage company focused on RNA-targeting gene therapies.

Locanabio recently presented new data at the 24th Annual Meeting of the American Society of Gene & Cell Therapy, including an RNA-targeting CRISPR/Cas13d gene therapy approach for skipping USH2A exon 13 for the treatment of retinal disease, as well as preclinical in vivo data demonstrating safety and efficacy of their novel PUF RNA-binding protein system delivered via an adeno-associated virus serotype 9 (AAV9) vector in eliminating toxic CUG repeats in a mouse model of myotonic dystrophy type 1.

In an interview with GeneTherapyLive, Burns commented on the changing landscape of gene therapy research, adding a poignant reminder of why the field continues to push forward.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.